Relmacabtagene Autoleucel for the Treatment of Systemic Sclerosis

Summary

Relma-cel is a product containing CD19-CAR-transduced T cells. The purpose of this study is to evaluate the safety of Relma-cel at different dose levels in patients with early diffuse systemic sclerosis. Efficacy will be explored too. If enrolled, participants will undergo leukapheresis, lymphodepleting chemotherapy and administration of Relma-cel.

Timeline

Start

2024-06-12

Primary completion

2025-05

Completion

2027-04

Drugs

Indications